
Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (CelerisTx One™ platform) to develop new chemical entities (NCEs) that degrade proteins by establishing proximity to endogenous cellular mechanisms. The solutions include machine learning-driven prediction of interactions, generative design, optimization of molecular properties, and automation of laboratory devices. CelerisTx's drug pipeline is focused on CNS and oncology, targeting unmet medical needs. We also co-develop…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.